renal-cell carcinoma (advanced) clinical trials results

apitolisib versus everolimus
Powles, 2014

versus
axitinib versus sorafenib
AXIS (Rini), 2011
NCT00678392
axitinib
versus
second-line therapy in patients with metastatic renal cell cancer
Qin, 2012

versus
bevacizumab versus placebo
Yang, 2003
bevacizumab at doses of 3 and 10 mg per kilogram of body weight, given every two weeks
versus
placebo
patients with metastatic renal-cell carcinoma
bevacizumab plus interferon alfa versus interferon alpha
CALGB 90206, 2010
bevacizumab (10 mg/kg intravenously every 2 weeks) plus IFN- (9 million units subcutaneously three times weekly)
versus
same dose and schedule of IFN- monotherapy
Patients with previously untreated, metastatic clear cell RCC
AVOREN, 2007
bevacizumab (10 mg/kg every 2 weeks) plus IFN (9 MIU subcutaneously three times a week)
versus
IFN plus placebo
patients with previously untreated mRCC
BNC105P + everolimus versus everolimus
Disruptor-1,

versus
cabozantinib versus everolimus
METEOR, 2015
NCT01865747
cabozantinib at a dose of 60 mg daily
versus
everolimus at a dose of 10 mg daily
patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapyopen-label
cabozantinib versus sunitinib
CABOSUN, 2017
NCT01835158
cabozantinib (60 mg once per day)
versus
sunitinib (50 mg once per day; 4 weeks on, 2 weeks off).
untreated clear cell mRCC and Eastern Cooperative Oncology Group performance status of 0 to 2 and were intermediate or poor risk per International Metastatic Renal Cell Carcinoma Database Consortium criteriaopen-label
dovitinib versus sorafenib
GOLD,
NCT01223027
dovitinib (500 mg orally according to a 5-days-on and 2-days-off schedule)
versus
sorafenib (400 mg orally twice daily)
patients with clear cell metastatic renal cell carcinoma who received one previous VEGF-targeted therapy and one previous mTOR inhibitor open-label
everolimus versus placebo
RECORD-1, 2008
NCT00410124
everolimus 10 mg once daily
versus
placebo
Patients with metastatic renal cell carcinoma which had progressed on sunitinib, sorafenib, or both
everolimus versus sunitinib
RECORD 3, 2014
NCT00903175
everolimus
versus
sunitinib
patients with metastatic renal cell carcinoma
nivolumab versus everolimus
CheckMate 025, 2015
NCT01668784
3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks
versus
10-mg everolimus tablet orally once daily
patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy
Chekmate 025 (Motzer), 2015
NCT01668784
3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks
versus
10-mg everolimus tablet orally once daily
patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy open-label
nivolumab + ipilimumab versus sunitinib
CheckMate-214, 2017
NCT02231749
nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by Opdivo 3 mg/kg every 2 weeks
versus
sunitinib 50 mg once daily for 4 weeks, followed by 2 weeks off before continuation of treatment
intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinomaopen-label
pazopanib versus placebo
Sternberg, 2010
pazopanib
versus
placebo
treatment-naive and cytokine-pretreated patients with advanced renal cell carcinomadouble-blind
VEG105192, 2010
NCT00334282

versus
treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma
pazopanib versus sunitinib
COMPARZ, 2013
NCT00720941
continuous dose of pazopanib (800 mg once daily)
versus
sunitinib in 6-week cycles (50 mg once daily for 4 weeks, followed by 2 weeks without treatment)
patients with clear-cell, metastatic renal-cell carcinoma, first line
sorafenib versus interferon alpha
Escudier, 2009
oral sorafenib 400 mg twice daily
versus
subcutaneous IFN--2a 9 million U three times weekly
patients with untreated, advanced renal cancer.
sorafenib versus placebo
TARGET, 2007
NCT00073307
continuous treatment with oral sorafenib (at a dose of 400 mg twice daily)
versus
placebo
patients with renal-cell carcinoma that was resistant to standard therapy
Ratain, 2006

versus
patients with metastatic renal cell carcinoma
sunitinib versus interferon alpha
Motzer, 2007
NCT00083889
repeated 6-week cycles of sunitinib (at a dose of 50 mg given orally once daily for 4 weeks, followed by 2 weeks without treatment)
versus
interferon alfa (at a dose of 9 MU given subcutaneously three times weekly).
patients with previously untreated, metastatic renal-cell carcinoma
sunitinib versus sorafenib
SWITCH,
NCT00732914

versus
temsirolimus versus interferon alpha
ARCC (Hudes) temsirolimus alone, 2007
NCT00065468
25 mg of intravenoustemsirolimus weekly
versus
3 million U of interferon alfa (with an increase to 18 millionU) subcutaneously three times weekly
patients with previously untreated, poor-prognosis metastatic renal-cell carcinoma
temsirolimus versus sorafenib
INTORSECT, 2014
NCT00474786
temsirolimus 25 mg once weekly by intravenous (IV) infusion
versus
sorafenib 400 mg PO twice daily
Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
tivozanib versus sorafenib
TIVO-1, 2013
NCT01030783
tivozanib
versus
sorafenib
initial targeted therapy in patients with metastatic renal cell carcinoma